CD34 and angina pectoris: A meta-analysis of those trials supported the therapeutic use of CD34+ cell therapy for cardiac ischemia after showing its superiority over placebos in reducing the risk of all-cause mortality and angina frequency, together with a prolongation of exercise time without increasing the incidence of adverse events [44].